Department of Biostatistics & Bioinformatics

Design. Analysis. Interpretation. Reporting.

From preclinical studies to epidemiology, the Department of Biostatistics and Bioinformatics at Roswell Park develops cutting-edge methods and software tools focused on cancer research.

With expertise across biology, medicine, statistics, mathematics and computer science, our faculty guide and participate in basic, translational, epidemiological and clinical trials research. Our department chair is Alan Hutson, Ph.D.

Meet our faculty Contact us Support our research

Dr. Alan Hutson, Chair of Biostatistics and Bioinformatics

“Our goal with the work we do every day at Roswell Park is to assess what the most pressing priorities are in data utilization and management, and then address those challenges and opportunities so we can support the biggest oncology advances of the next decade.”

Meet our Chair: Dr. Alan Hutson

Data-driven expertise across five divisions

Biostatistics and Statistical Genomics

Developing, overseeing, implementing, analyzing, publishing and reporting Roswell Park’s scientific studies. Co-directed by Dr. Qianqian Zhu and Dr. Han Yu.

Learn more

Bioinformatics

Designing, analyzing, and interpretating genomics, proteomics, and other high-resolution, high-throughput based studies. Led by Dr. Song Liu.

Learn more

Biomedical Research Information

Creating innovative informatics tools that optimize data acquisition, data quality and data curation. Led by Dr. Sarah Mullin.

Learn more

Bioconductor Project

Providing tools for the analysis and comprehension of high-throughput genomic data. Led by Dr. Martin Morgan.

Learn more

Clinical Trial Development Division (CTDD)

Working with investigators and sponsors to develop, conduct, monitor and report clinical trials. Led by Angela Kuras.

Learn more

“The r/Bioconductor project enables researchers worldwide to develop, share and use leading-edge statistical approaches and to place the insights we gain from these tools into their appropriate contexts so we can support medical research that’s both more accurate and more actionable.”

Meet Dr. Martin Morgan

Unmatched clinical trials management

The Clinical Trial Development Division (CTDD), under the direction of Virginia Filiaci, PhD, works with investigators and sponsors to develop, conduct, monitor and report clinical trials. Our experienced team provides full statistical, data management, project management and quality assurance collaboration on multi-center clinical trials.

Multi-center cancer clinical trials

450+

Patient registrations

113,000+

Phase 3 trials

120+

CTDD also offers an efficient and cost-effective budgeting process and access to a 21 CFR Part 11 compliant electronic data collection option for NCI funded clinical trials.

Far-reaching research networks

Roswell Park’s Department of Biostatistics and Bioinformatics also houses several large-scale collaboration projects, including participation in the National Cancer Institute’s Cancer Moonshot Initiative.

NRG Oncology Network

Conducting practice-changing multi-institutional clinical and translational research

Learn more

Immunology Oncology Translational Network

Advancing research progress to improve immunotherapy and immunoprevention

Learn more

Acquired Resistance to Therapy Network

ARTNet focuses on the mechanistic bases of acquired resistance to cancer therapies and disease recurrence.

Learn more

Cancer Prevention-Interception Targeted Agent Discovery Program

CAP-IT seeks to establish a new discovery research paradigm in cancer prevention.

Learn more

Training the next generation of scientists

In addition to our research and community outreach, the Department of Biostatistics and Bioinformatics is actively involved in hands-on teaching with Master’s and PhD students in our highly competitive graduate studies program.

Our faculty also work closely with the University at Buffalo’s Biostatistics Department, training and mentoring numerous UB doctoral candidates.

Our multidisciplinary education model allows students a unique immersive experience, preparing them for successful careers as independent investigators. 

Education Meet our faculty

See the science

Long Lab

Rosario Lab

Wei Lab

Selected publications

Annapragada A, Sikora AG, Marathe H, Liu S (TII), Demetriou M, Fong L, Gao J, Kufe D, Morris ZS, Vilar E, Sharon E, Hutson A (DT), Odunsi K. The Cancer Moonshot Immuno-Oncology Translational Network (IOTN) at age 5: Accelerating Cancer Immunotherapies. J Natl Cancer Inst. 2023 AUG 12; . DOI: 10.1093/jnci/djad151. 2023 Aug 12. PubMed PMID: 37572314.
McGray AJR, Chiello JL, Tsuji T, Long M (CSB), Maraszek K, Gaulin N, Rosario SR (CSB), Hess SM, Abrams SI (TII), Kozbor D (TII), Odunsi K, Zsiros E (TII). BiTE secretion by adoptively transferred stem-like T cells improves FRα+ ovarian cancer control. J Immunother Cancer. 2023 JUN 01; 11(6). DOI: 10.1136/jitc-2023-006863. 2023 Jun 23. PubMed PMID: 37647218; PMCID: PMC10314690.
Li F (DT), Ling X, Chakraborty S (DT), Fountzilas C (DT), Wang J (DT), Jamroze A, Liu X, Kalinski P (TII), Tang DG (DT). Role of the DEAD-box RNA helicase DDX5 (p68) in cancer DNA repair, immune suppression, cancer metabolic control, virus infection promotion, and human microbiome (microbiota) negative influence. J Exp Clin Cancer Res. 2023 AUG 19; 42(1):213. DOI: 10.1186/s13046-023-02787-x. 2023 Aug 19. PubMed PMID: 37596619; PMCID: PMC10439624.
Rawat C, Ben-Salem S, Singh N, Chauhan G, Rabljenovic A, Vaghela V, Venkadakrishnan VB, Macdonald JD, Dahiya UR, Ghanem Y, Bachour S, Su Y, DePriest AD, Lee S, Muldong M, Kim HT, Kumari S, Valenzuela MM, Zhang D, Hu Q, Cortes Gomez E, Dehm SM, Zoubeidi A, Jamieson CAM, Nicolas M, McKenney J, Willard B, Klein EA, Magi-Galluzzi C, Stauffer SR, Liu S (TII), Heemers HV. Prostate cancer progression relies on the mitotic kinase citron kinase. Cancer Res. 2023 OCT 06; . DOI: 10.1158/0008-5472.CAN-23-0883. 2023 Oct 6. PubMed PMID: 37801613.
Wu R, Oshi M, Asaoka M, Yan L (PS), Benesch MGK, Khoury T, Nagahashi M, Miyoshi Y, Endo I, Ishikawa T, Takabe K (DT). Intratumoral Tumor Infiltrating Lymphocytes (TILs) are Associated With Cell Proliferation and Better Survival But Not Always With Chemotherapy Response in Breast Cancer. Ann Surg. 2023 OCT 01; 278(4):587-597. DOI: 10.1097/SLA.0000000000005954. 2023 Jun 15. PubMed PMID: 37318852; PMCID: PMC10481934.
Boucher Y, Posada JM, Subudhi S, Kumar AS, Rosario SR (CSB), Gu L, Kumra H, Mino-Kenudson M, Talele NP, Duda DG, Fukumura D, Wo JY, Clark JW, Ryan DP, Fernandez-Del Castillo C, Hong TS, Pittet MJ, Jain RK. Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Cancer Cells in Locally Advanced Pancreatic Cancer. Clin Cancer Res. 2023 APR 14; 29(8):1605-1619. DOI: 10.1158/1078-0432.CCR-22-1630. PubMed PMID: 36749873; PMCID: PMC10106451.
Landen CN, Molinero L, Hamidi H, Sehouli J, Miller A, Moore KN, Taskiran C, Bookman M, Lindemann K, Anderson C, Berger R, Myers T, Beiner M, Reid T, Van Nieuwenhuysen E, Green A, Okamoto A, Aghajanian C, Thaker PH, Blank SV, Khor VK, Chang CW, Lin YG, Pignata S. Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial. Clin Cancer Res. 2023 MAY 01; 29(9):1698-1707. DOI: 10.1158/1078-0432.CCR-22-2032. PubMed PMID: 36595569; PMCID: PMC10150250.
Ge Y, Chen X, Nan N, Bard J, Wu F, Yergeau D, Liu T (DT), Wang J, Mu X. Key transcription factors influence the epigenetic landscape to regulate retinal cell differentiation. Nucleic Acids Res. 2023 MAR 21; 51(5):2151-2176. DOI: 10.1093/nar/gkad026. PubMed PMID: 36715342; PMCID: PMC10018358.
Luzhin A, Rajan P, Safina A, Leonova K, Stablewski A (TII), Wang J (DT), Robinson D, Isaeva N, Kantidze O, Gurova K (CSB). Comparison of cell response to chromatin and DNA damage. Nucleic Acids Res. 2023 OCT 19; . DOI: 10.1093/nar/gkad865. 2023 Oct 19. PubMed PMID: 37855682.
Ahluwalia MS, Reardon DA, Abad AP, Curry WT, Wong ET, Figel SA, Mechtler LL, Peereboom DM, Hutson AD (DT), Withers HG, Liu S (TII), Belal AN, Qiu J, Mogensen KM, Dharma SS, Dhawan A, Birkemeier MT, Casucci DM, Ciesielski MJ (TII), Fenstermaker RA (TII). Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma. J Clin Oncol. 2023 MAR 01; 41(7):1453-1465. DOI: 10.1200/JCO.22.00996. 2022 Dec 15. PubMed PMID: 36521103; PMCID: PMC9995096.
Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel R, Shahin MS, Cantuaria GH, Girda E, Mathews C, Kavecansky J, Leath CA, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Al Baghdadi T, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. N Engl J Med. 2023 JUN 08; 388(23):2159-2170. DOI: 10.1056/NEJMoa2302312. 2023 Mar 27. PubMed PMID: 36972022; PMCID: PMC10351614.
Krishnan K, Shi T, Yu H (CSB), Hageman Blair R. Integrated Graph Propagation and Optimization with Biological Applications. Pac Symp Biocomput. 2023 JAN 01; 28:169-180. PubMed PMID: 36540974.
Luzhin A, Rajan P, Safina A, Leonova K, Stablewski A (TII), Wang J (DT), Pal M, Kantidze O, Gurova K (CSB). Comparison of cell response to chromatin and DNA damage. bioRxiv. 2023 JAN 18; . DOI: 10.1101/2023.01.17.524424. 2023 Jan 18. PubMed PMID: 36711582; PMCID: PMC9882266.
Abdelfatah E, Long MD (CSB), Kajihara R, Oba T, Yamauchi T, Chen H, Sarkar J, Attwood K (DT), Matsuzaki J, Segal BH (TII), Dy GK (DT), Ito F. Predictive and Prognostic Implications of Circulating CX3CR1+ CD8+ T Cells in Non-Small Cell Lung Cancer Patients Treated with Chemo-Immunotherapy. Cancer Res Commun. 2023 MAR 01; 3(3):510-520. DOI: 10.1158/2767-9764.CRC-22-0383. 2023 Mar 30. PubMed PMID: 37009132; PMCID: PMC10060186.
Kirk JS, Wang J, Tracz A, Long M (CSB), Rosario SR (CSB), Ji Y, Kumar R, Liu X, Singh PK, Puzanov I (DT), Chatta G (DT), Cheng Q, Huang J, Wrana JL, Lovell J, Yu H (CSB), Liu S (TII), Shen MM, Liu T (DT), Tang DG (DT). Integrated single-cell analysis defines the epigenetic basis of castration-resistant prostate luminal cells. bioRxiv. 2023 MAR 06; . DOI: 10.1101/2023.03.03.530998. 2023 Mar 6. PubMed PMID: 36945493; PMCID: PMC10028794.
Afiaz A, Ivanov AA, Chamberlin J, Hanauer D, Savonen CL, Goldman MJ, Morgan M (TII), Reich M, Getka A, Holmes A, Pati S, Knight D, Boutros PC, Bakas S, Caporaso JG, Del Fiol G, Hochheiser H, Haas B, Schloss PD, Eddy JA, Albrecht J, Fedorov A, Waldron L, Hoffman AM, Bradshaw RL, Leek JT, Wright C. Evaluation of software impact designed for biomedical research: Are we measuring what's meaningful? ArXiv. 2023 JUN 05; . 2023 Jun 5. PubMed PMID: 37332562; PMCID: PMC10274942.
Padgett LR, Shinkle MR, Rosario S (CSB), Stewart TM, Foley JR, Casero RA, Park MH, Chung WK, Mastracci TL. Deoxyhypusine synthase mutations alter the post-translational modification of eukaryotic initiation factor 5A resulting in impaired human and mouse neural homeostasis. HGG Adv. 2023 JUL 13; 4(3):100206. DOI: 10.1016/j.xhgg.2023.100206. 2023 May 18. PubMed PMID: 37333770; PMCID: PMC10275725.
Hutson A (DT), Yu H (CSB), Attwood K (DT). Leveraging Homologous Hypotheses for Increased Efficiency in Tumor Growth Curve Testing. Res Sq. 2023 AUG 17; . DOI: 10.21203/rs.3.rs-3242375/v1. 2023 Aug 17. PubMed PMID: 37645958; PMCID: PMC10462185.
Flynn PA, Long MD (CSB), Kosaka Y, Mulkey JS, Coy JL, Agarwal A, Lind EF. Leukemic mutation FLT3-ITD is retained in dendritic cells and disrupts their homeostasis leading to expanded Th17 frequency. bioRxiv. 2023 SEP 22; . DOI: 10.1101/2023.09.19.558512. 2023 Sep 22. PubMed PMID: 37781631; PMCID: PMC10541139.
Takeshita T, Iwase H, Wu R, Ziazadeh D, Yan L (PS), Takabe K (DT). Development of a Machine Learning-Based Prognostic Model for Hormone Receptor-Positive Breast Cancer Using Nine-Gene Expression Signature. World J Oncol. 2023 OCT 01; 14(5):406-422. DOI: 10.14740/wjon1700. 2023 Sep 20. PubMed PMID: 37869243; PMCID: PMC10588506.
Shadpour S, Shafqat A, Toy S, Jing Z, Attwood K (DT), Moussavi Z, Shafiei SB. Developing cognitive workload and performance evaluation models using functional brain network analysis. NPJ Aging. 2023 OCT 06; 9(1):22. DOI: 10.1038/s41514-023-00119-z. 2023 Oct 6. PubMed PMID: 37803137; PMCID: PMC10558559.
Vylegzhanina A, Bespalov I, Novototskaya-Vlasova K, Hall BM, Gleiberman A, Yu H (CSB), Leontieva O, Leonova KI, Kurnasov O, Osterman AL, Dy GK (DT), Komissarov AA, Vasilieva E, Gehlhausen JR, Iwasaki A, Ambrosone CB (PS), Tsuji T, Matsuzaki J, Odunsi K, Andrianova E, Gudkov AV (CSB). Cancer relevance of circulating antibodies against LINE-1 antigens in humans. Cancer Res Commun. 2023 OCT 23; . DOI: 10.1158/2767-9764.CRC-23-0289. 2023 Oct 23. PubMed PMID: 37870410.

Liu JF, Brady MF, Matulonis UA, Miller A (TII), Kohn EC, Swisher EM, Cella D, Tew WP, Cloven NG, Muller CY, Bender DP, Moore RG, Michelin DP, Waggoner SE, Geller MA, Fujiwara K, D'Andre SD, Carney M, Alvarez Secord A, Moxley KM, Bookman MA. Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2022 JUL 01; 40(19):2138-2147. DOI: 10.1200/JCO.21.02011. 2022 Mar 15. PubMed PMID: 35290101; PMCID: PMC9242406.
Gershenson DM, Miller A (TII), Brady WE, Paul J, Carty K, Rodgers W, Millan D, Coleman RL, Moore KN, Banerjee S, Connolly K, Secord AA, O'Malley DM, Dorigo O, Gaillard S, Gabra H, Slomovitz B, Hanjani P, Farley J, Churchman M, Ewing A, Hollis RL, Herrington CS, Huang HQ, Wenzel L, Gourley C. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet. 2022 FEB 05; 399(10324):541-553. DOI: 10.1016/S0140-6736(21)02175-9. PubMed PMID: 35123694; PMCID: PMC8819271.
Pokhare S, Sharma UC, Attwood K (DT), Mansoor S. Clinical Significance of Galectin-3 Expression in Squamous Cell Carcinoma of Lung. J Cancer Sci Clin Ther. 2022 JAN 01; 6(3):322-327. DOI: 10.26502/jcsct.5079169. 2022 Aug 22. PubMed PMID: 36081447; PMCID: PMC9451108.
Hagoel TJ, Cortes Gomez E, Gupta A (DT), Twist CJ (DT), Kozielski R, Martin JC, Gao L, Kuechle J, Singh PK, Lynch M, Wei L (CSB), Liu S (TII), Wang J (DT), Ohm JE (CSB). Clinicopathologic and molecular analysis of a BCOR-CCNB3 undifferentiated sarcoma of the kidney reveals significant epigenetic alterations. Cold Spring Harb Mol Case Stud. 2022 JAN 01; 8(1). DOI: 10.1101/mcs.a005942. 2022 Jan 10. PubMed PMID: 34819304; PMCID: PMC8744494.
Elkin PL, Resendez S, Mullin S (CSB), Troen BR, Mammen MJ, Chang S, Franklin G, McCray W, Brown SH. Leukotriene inhibitors with dexamethasone show promise in the prevention of death in COVID-19 patients with low oxygen saturations. J Clin Transl Sci. 2022 JAN 01; 6(1):e74. DOI: 10.1017/cts.2022.401. 2022 May 16. PubMed PMID: 35836784; PMCID: PMC9274389.
Schatz MC, Philippakis AA, Afgan E, Banks E, Carey VJ, Carroll RJ, Culotti A, Ellrott K, Goecks J, Grossman RL, Hall IM, Hansen KD, Lawson J, Leek JT, Luria AO, Mosher S, Morgan M (TII), Nekrutenko A, O'Connor BD, Osborn K, Paten B, Patterson C, Tan FJ, Taylor CO, Vessio J, Waldron L, Wang T, Wuichet K. Inverting the model of genomics data sharing with the NHGRI Genomic Data Science Analysis, Visualization, and Informatics Lab-space. Cell Genom. 2022 JAN 12; 2(1). DOI: 10.1016/j.xgen.2021.100085. 2022 Jan 13. PubMed PMID: 35199087; PMCID: PMC8863334.
Pugh SL, Brown PD, Enserro D. Missing repeated measures data in clinical trials. Neurooncol Pract. 2022 FEB 01; 9(1):35-42. DOI: 10.1093/nop/npab043. 2021 Jul 16. PubMed PMID: 35096402; PMCID: PMC8789297.
Athans S, Krishnan N, Ramakrishnan S, Cortes Gomez E, Lage-Vickers S, Rak M, Kazmierczak Z, Ohm J (CSB), Attwood K (DT), Wang J (DT), Woloszynska A (DT). STAG2 expression is associated with adverse survival outcomes and regulates cell phenotype in muscle-invasive bladder cancer. Cancer Res Commun. 2022 OCT 01; 2(10):1129-1143. DOI: 10.1158/2767-9764.crc-22-0155. 2022 Oct 6. PubMed PMID: 36275363; PMCID: PMC9583756.

Duska LR, Filiaci VL, Walker JL, Holman LL, Hill EK, Moore RG, Ring K, Pearl ML, Muller CY, Kushnir CL, Lankes HA, Samuelson MI, Carrick KS, Kanagasabapathy DR, Rodgers WH, Kohn E, Piekarz R, Leslie KK. A Surgical Window Trial Evaluating medroxyprogesterone acetate with or without Entinostat in Endometrial Cancer and Validation of Biomarkers of Cellular Response: An NRG Oncology Study. Accepted by journal, Jan 2021.
Yamashita N, Long M, Fushimi A, Yamamoto M, Hata T, Hagiwara M, Bhattacharya A, Hu Q, Wong KK*, Liu S*, Kufe D*. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer. Journal for ImmunoTherapy of Cancer. 2021; 9(1):e002115.
Pan Y, Kadash-Edmondson K, Wang R, Phillips J, Liu S, Ribas A, Aplenc R, Witte O, Xing Y. RNA Dysregulation: An Expanding Source of Cancer Immunotherapy Targets. Trends in Pharmacological Sciences 2021; 42(4), 268-282. PMID: 33711255 DOI: 10.1016/j.tips.2021.01.006
Zsiros E, Lynam S, Attwood KM, Wang C, Chilakapati S, Gomez EC, Liu S, Akers S, Lele S, Frederick PJ, Odunsi K. Efficacy and Safety of Pembrolizumab in Combination with Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncology 2021;7(1):78-85. PMID: 33211063 PMCID: PMC7677872 DOI: 10.1001/jamaoncol.2020.5945
Zhou Y, Bastian IN, Long MD, Dow M, Li W, Liu T, Ngu RK, Antonucci L, Huang JY, Phung QT, Zhao XH, Banerjee S, Lin XJ, Wang H, Dang B, Choi S, Karin D, Su H, Ellisman MH, Jamieson C, Bosenberg M, Cheng Z, Haybaeck J, Kenner L, Fisch KM, Bourgon R, Hernandez G, Lill JR, Liu S, Carter H, Mellman I, Karin M, Shalapour S. Activation of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation. Proceedings of the National Academy of Sciences. 2021;118(8):e2025840118. PMID: 33602823 PMCID: PMC7923353 DOI: 10.1073/pnas.2025840118
Wei L, Christensen SR, Fitzgerald ME, Graham J, Hutson ND, Zhang C, Huang Z, Hu Q, Zhan F, Xie J, Zhang J, Liu S, Remenyik E, Gellen E, Colegio OR, Bax M, Xu J, Lin H, Huss WJ, Foster BA, Paragh G. Ultradeep sequencing differentiates patterns of skin clonal mutations associated with sun-exposure status and skin cancer burden. Science Advances 2021 Jan 1;7(1):eabd7703. DOI: 10.1126/sciadv.abd7703
Merritt MA, Strickler HD, Hutson AD, Einstein MH, Rohan TE, Xue X, Sherman ME, Brinton LA, Yu H, Miller DS, Ramirez NC, Lankes HA, Birrer MJ, Huang GS, Gunter MJ. Sex Hormone, Insulin and Insulin-like Growth Factor in Recurrence of High Stage Endometrial Cancer. Cancer Epidemiol Biomarkers Prev. 2021 Feb 23:cebp.EPI-20-1613-E.2020. doi: 10.1158/1055-9965.EPI-20-1613. PMID: 33622671
Hutson AD, Yu H. A robust permutation test for the concordance correlation coefficient. Pharm Stat. 2021 Feb 17. doi: 10.1002/pst.2101. PMID: 33599032
Carter J, Huang HQ, Armer J, Carlson JW, Lockwood S, Nolte S, Kauderer J, Hutson A, Walker JL, Fleury AC, Bonebrake A, Soper JT, Mathews C, Zivanovic O, Richards WE, Tan A, Alberts DS, Barakat RR, Wenzel LB. GOG 244 - The Lymphedema and Gynecologic cancer (LeG) study: The impact of lower-extremity lymphedema on quality of life, psychological adjustment, physical disability, and function. Gynecol Oncol. 2021 Jan;160(1):244-251. doi: 10.1016/j.ygyno.2020.10.023. Epub 2020 Oct 24. PMID: 33109392
Wu F, Bard JE, Kann J, Yergeau D, Sapkota D, Ge Y, Hu Z, Wang J, Liu T, Mu X. Single cell transcriptomics reveals lineage trajectory of retinal ganglion cells in wild-type and Atoh7-null retinas. Nat Commun. 2021 Mar 5;12(1):1465. doi: 10.1038/s41467-021-21704-4. PubMed PMID: 33674582.
Zhou Y, Bastian IN, Long MD, Dow M, Li W, Liu T, Ngu RK, Antonucci L, Huang JY, Phung QT, Zhao XH, Banerjee S, Lin XJ, Wang H, Dang B, Choi S, Karin D, Su H, Ellisman MH, Jamieson C, Bosenberg M, Cheng Z, Haybaeck J, Kenner L, Fisch KM, Bourgon R, Hernandez G, Lill JR, Liu S, Carter H, Mellman I, Karin M, Shalapour S. Activation of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation. Proc Natl Acad Sci U S A. 2021 Feb 23;118(8). doi: 10.1073/pnas.2025840118. PMID: 33602823; PMCID: PMC7923353.
Zhou Y, Bastian IN, Long MD, Dow M, Li W, Liu T, Ngu RK, Antonucci L, Huang JY, Phung QT, Zhao XH, Banerjee S, Lin XJ, Wang H, Dang B, Choi S, Karin D, Su H, Ellisman MH, Jamieson C, Bosenberg M, Cheng Z, Haybaeck J, Kenner L, Fisch KM, Bourgon R, Hernandez G, Lill JR, Liu S, Carter H, Mellman I, Karin M, Shalapour S. Activation of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation. Proc Natl Acad Sci U S A. 2021 Feb 23;118(8). doi: 10.1073/pnas.2025840118. PubMed PMID: 33602823; PubMed Central PMCID: PMC7923353.
Wang X, Jin L, Hu C, Shen S, Qian S, Ma M, Zhu X, Li F, Wang J, Tian Y, Qu J. Ultra-High-Resolution IonStar Strategy Enhancing Accuracy and Precision of MS1-Based Proteomics and an Extensive Comparison with State-of-the-Art SWATH-MS in Large-Cohort Quantification. Anal Chem. 2021 Mar 23;93(11):4884-4893. doi: 10.1021/acs.analchem.0c05002. Epub 2021 Mar 9. PubMed PMID: 33687211.
Alqassim EY, Sharma S, Khan ANMNH, Emmons TR, Cortes Gomez E, Alahmari A, Singel KL, Mark J, Davidson BA, Robert McGray AJ, Liu Q, Lichty BD, Moysich KB, Wang J, Odunsi K, Segal BH, Baysal BE. RNA editing enzyme APOBEC3A promotes pro-inflammatory M1 macrophage polarization. Commun Biol. 2021 Jan 22;4(1):102. doi: 10.1038/s42003-020-01620-x. PMID: 33483601; PMCID: PMC7822933.
Li F, Zhao X, Zhang Y, Shao P, Ma X, Paradee WJ, Liu C, Wang J, Xue HH. TFH cells depend on Tcf1-intrinsic HDAC activity to suppress CTLA4 and guard B-cell help function. Proc Natl Acad Sci U S A. 2021 Jan 12;118(2). doi: 10.1073/pnas.2014562118. PMID: 33372138; PMCID: PMC7812797.
Farrugia MK, Long MD, Mattson DM, Flaherty LT, Dong B, Cortes Gomez E, Wei L, Witkiewicz AK, Yao S, Kalinski P, Singh AK. Concurrent Aspirin Use Is Associated with Improved Outcome in Rectal Cancer Patients Who Undergo Chemoradiation Therapy. Cancers (Basel). 2021 Jan 8;13(2). doi: 10.3390/cancers13020205. PubMed PMID: 33430037; PubMed Central PMCID: PMC7826684.
Wei L, Christensen SR, Fitzgerald ME, Graham J, Hutson ND, Zhang C, Huang Z, Hu Q, Zhan F, Xie J, Zhang J, Liu S, Remenyik E, Gellen E, Colegio OR, Bax M, Xu J, Lin H, Huss WJ, Foster BA, Paragh G. Ultradeep sequencing differentiates patterns of skin clonal mutations associated with sun-exposure status and skin cancer burden. Sci Adv. 2021 Jan;7(1). doi: 10.1126/sciadv.abd7703. Print 2021 Jan. PubMed PMID: 33523857; PubMed Central PMCID: PMC7775785.
Pathak R, De Lima Lopes G, Yu H, Aryal MR, Ji W, Frumento KS, Wallis CJD, Klaassen Z, Park HS, Goldberg SB. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials. Cancer. 2021 Mar 1;127(5):709-719. doi: 10.1002/cncr.33269. Epub 2020 Oct 29. PubMed PMID: 33119177.
Leslie KK, Filiaci VL, Mallen AR, Thiel KW, Devor EJ, Moxley K, Richardson D, Mutch D, Secord AA, Tewari KS, McDonald ME, Mathews C, Cosgrove C, Dewdney S, Casablanca Y, Jackson A, Rose PG, Zhou X, McHale M, Lankes H, Levine DA, Aghajanian C. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. Gynecol Oncol. 2021 Feb 1;. doi: 10.1016/j.ygyno.2021.01.025. [Epub ahead of print] Review. PubMed PMID: 33541735.

Miller DS, Filiaci VL, Fleming GF, Mannel RS, Cohn D, Matsumoto T, Tewari KS, DiSilvestro PA, Pearl ML, Argenta PA, Powell MA, Zweizig SL, Warshal DP, Hanjani P, Carney ME, Zaino RJ. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209) J Clin Oncol. 2020 Nov 20;38(33):3841-3850. doi: 10.1200/JCO.20.01076. Epub 2020 Sep 29. PMID: 33078978; PMCID: PMC7676887. Editor’s Pick.
Madhombiro M, Kidd M, Dube B, Dube M, Mutsvuke W, Muronzie T, Zhou DT, Derveeuw S, Chibanda D, Chingono A, Rusakaniko S, Hutson A, Morse GD, Abas MA, Seedat S. Effectiveness of a psychological intervention delivered by general nurses for alcohol use disorders in people living with HIV in Zimbabwe: a cluster randomized controlled trial. J Int AIDS Soc. 2020 Dec;23(12):e25641. doi: 10.1002/jia2.25641. PMID: 33314786
Kalathil SG, Wang K, Hutson A, Iyer R, Thanavala Y. Tivozanib mediated inhibition of c-Kit/SCF signaling on Tregs and MDSCs and reversal of tumor induced immune suppression correlates with survival of HCC patients. Oncoimmunology. 2020 Sep 30;9(1):1824863. doi: 10.1080/2162402X.2020.1824863. PMID: 33101775
Arring NM, Millstine D, Barton DL, Lyons KS, Girardo M, Hutson A, Nail LM. Trends in integrative medicine and health consults: differences between cancer survivors and patients without cancer. Support Care Cancer. 2020 Oct 14. doi: 10.1007/s00520-020-05815-0. PMID: 33057818
Attwood K and Tian L. Confidence Interval Estimation of the Youden index and corresponding cut-point for a combination of biomarkers under normality. Communications in Statistics – Theory and Methods. 2020. DOI: 10.1080/03610926.2020.1751852.
Elsayed AS, Jing Z, Demirbas D, Durrani M, Attwood K, Cilento J, Osei J, Gison S, Mostowy M, Christophe A, Hussein and Guru K. Development and Cross-Validation of a Nomogram for Chronic Kidney Disease Following Robot-Assisted Radical Cystectomy. Journal of Endourology 2020. PMID: 32631086 DOI: 10.1089/end.2020.0451.
Gunn J, Lemini R, Partain K, Yeager T, Almerey T, Attwood K, McLaughlin S, Bagaria SP and Gabriel E. Trends in utilization of sentinel node biopsy and adjuvant radiation in women ≥ 70. The Breast Journal 2020; doi: 10.1111/tbj.13750.
Cejas RB, Wang J, Hageman-Blair R, Liu S, Blanco JG. Comparative genome-wide DNA methylation analysis in myocardial tissue from donors with and without Down syndrome. Gene. 2021 Jan 5;764:145099. doi: 10.1016/j.gene.2020.145099. Epub 2020 Aug 27. PubMed PMID: 32861879; NIHMSID:NIHMS1628462.
Etter, J.L., Moysich, K., Kohli, S., Lele, S., Odunsi, K. & Eng, K.H. (2020). Transmission of X-linked Ovarian Cancer: Characterization and Implications Affiliations expand. Diagnostics (Basel), 10(2), 90. PMCID: PMC7167857.
Srivastava P, Tzetzo SL, Gomez EC, Eng KH, Jani Sait SN, Kuechle JB, Singh PK, De Jong K, Wiatrowski KR, Peresie J, Dimitroff A, Lynch ML, Wang J, Abrams SI, Griffiths EA, Nemeth MJ. Inhibition of LSD1 in MDS progenitors restores differentiation of CD141Hi conventional dendritic cells. Leukemia. 2020 Sep;34(9):2460-2472. doi: 10.1038/s41375-020-0765-5. Epub 2020 Feb 25. PMID: 32099035; PMCID: PMC7483249.
Tsuji T, Eng KH, Matsuzaki J, Battaglia S, Szender JB, Miliotto A, Gnjatic S, Bshara W, Morrison CD, Lele S, Emerson RO, Wang J, Liu S, Robins H, Lugade AA, Odunsi K. Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer. Oncotarget. 2020 Jul 7;11(27):2669-2683. doi: 10.18632/oncotarget.27666. eCollection 2020 Jul 7. PMID: 32676168; PMCID: PMC7343634.
Wang C, Sun D, Huang X, Wan C, Li Z, Han Y, Qin Q, Fan J, Qiu X, Xie Y, Meyer CA, Brown M, Tang M, Long H, Liu T, Liu XS. Integrative analyses of single-cell transcriptome and regulome using MAESTRO. Genome Biol. 2020 Aug 7;21(1):198. doi: 10.1186/s13059-020-02116-x. PMID: 32767996; PMCID: PMC7412809.
Zhu Q, Zhang J, Chen Y, Hu Q, Shen H, Huang RY, Liu Q, Kaur J, Long M, Battaglia S, Eng KH, Lele SB, Zsiros E, Villella J, Lugade A, Yao S, Liu S, Moysich K, Odunsi KO. Whole-exome sequencing of ovarian cancer families uncovers putative predisposition genes. Int J Cancer, 2020; 146(8):2147-2155. PMCID: PMC7065147
Schink JC, Filiaci V, Huang HQ, Tidy J, Winter M, Carter J, Anderson N, Moxley K, Yabuno A, Taylor SE, Kushnir C, Horowitz N, Miller DS. An International Randomized Phase III Trial of Pulse Actinomycin-D versus Multi-day Methotrexate for the Treatment of Low Risk Gestational Trophoblastic Neoplasia; NRG/GOG 275. Gynecol Oncol. 2020 Aug;158(2):354-360; doi: 10.1016/j.ygyno.2020.05.013. Epub 2020 May 24. PMID: 32460997; PMCID: PMC7432963.
Miller DS, Randall ME, Filiaci V. Progress in endometrial cancer: Contributions of the former Gynecologic Oncology Group. Gynecol Oncol 2020 157(2):p312-322 pii: S0090-8258(20)30019-6. doi: 10.1016/j.ygyno.2020.01.012. PMID: 32014330
Santin A, Filiaci V, Bellone S, O'Cearbhaill R, Ratner ES, Mathews C, Cantuaria G, Gunderson CC, Rutledge T, Buttin BM, Lankes HA, Birrer MJ. Phase II Evaluation of Copanlisib, a Selective Inhibitor of Pi3kca, in Patients with Persistent or Recurrent Endometrial Carcinoma Harboring Pik3ca Hotspot Mutations: An NRG Oncology Study. Gynecol Oncol Rep. 2020 Jan 2;31:100532. doi: 10.1016/j.gore.2019.100532. eCollection 2020 Feb. PMID: 31934607 PMCID: PMC6951478

Contact us

Meegan Michalek Becker, MA
Department Administrator
Phone: 716-845-1090
Email: Meegan.Becker@RoswellPark.org

Lauren Sibolski
Administrative Assistant
Phone: 716-845-2704
Email: Lauren.Sibolski@RoswellPark.org